Where can I find news about BIIB?

The latest headlines, third-party analysis, and SEC filings for Biogen Inc. (BIIB) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are BIIB's SEC filings?

Biogen Inc. (BIIB)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are BIIB's earnings call transcripts?

Full earnings call transcripts for Biogen Inc. (BIIB) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

BIIB

Biogen Inc.

NASDAQ·Drug Manufacturers, General · Healthcare

$220.83$3.68−1.64%

Market cap$32.63B·Market closed·Sep 4 8:00 PM UTC

News & Analysis

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
gurufocus.comSep 3, 2026 · 8:00 PM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines –
globenewswire.comSep 3, 2026 · 7:30 PM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet.
businesswire.comSep 3, 2026 · 7:30 PM
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease
globenewswire.comSep 3, 2026 · 12:00 AM
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
globenewswire.comSep 1, 2026 · 7:30 AM
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
globenewswire.comAug 31, 2026 · 7:30 PM
Canada Pension Plan Investment Board Makes New Investment in Biogen Inc. $BIIB
Canada Pension Plan Investment Board purchased a new position in shares of Biogen Inc. (NASDAQ: BIIB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,602 shares of the biotechnology company's stock, valued at approximately $2,939,000. Several other hedge funds and other
defenseworld.netAug 31, 2026 · 4:30 AM
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
zacks.comAug 28, 2026 · 12:36 PM

SEC Filings

SC 13G/A
Aug 6, 2026View on SEC
10-Q
Jul 29, 2026View on SEC
8-K
Jul 29, 2026View on SEC
8-K
Jul 1, 2026View on SEC
8-K
Jun 10, 2026View on SEC
8-K/A
Jun 10, 2026View on SEC

Frequently Asked Questions About BIIB

Where can I find news about BIIB?: The latest headlines, third-party analysis, and SEC filings for Biogen Inc. (BIIB) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are BIIB's SEC filings?: Biogen Inc. (BIIB)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are BIIB's earnings call transcripts?: Full earnings call transcripts for Biogen Inc. (BIIB) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Biogen Inc.

Frequently Asked Questions About BIIB

Biogen Inc.

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

Canada Pension Plan Investment Board Makes New Investment in Biogen Inc. $BIIB

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?

Frequently Asked Questions About BIIB

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease

Canada Pension Plan Investment Board Makes New Investment in Biogen Inc. $BIIB

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?